nach oben

Erschienen in:

01.11.2015 | Topic Review

MicroRNA as potential biomarkers in Glioblastoma

verfasst von: Zammam Areeb, Stanley S. Stylli, Rachel Koldej, David S. Ritchie, Tali Siegal, Andrew P. Morokoff, Andrew H. Kaye, Rodney B. Luwor

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Glioblastoma is the most aggressive and lethal tumour of the central nervous system and as such the identification of reliable prognostic and predictive biomarkers for patient survival and tumour recurrence is paramount. MicroRNA detection has rapidly emerged as potential biomarkers, in patients with glioblastoma. Over the last decade, analysis of miRNA in laboratory based studies have yielded several candidates as potential biomarkers however, the accepted use of these candidates in the clinic is yet to be validated. Here we will examine the use of miRNA signatures to improve glioblastoma stratification into subgroups and summarise recent advances made in miRNA examination as potential biomarkers for glioblastoma progression and recurrence.

Goodenberger ML, Jenkins RB (2012) Genetics of adult glioma. Cancer Genet. 205(12):613–621PubMedCrossRef

Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY (2012) Primary brain tumours in adults. Lancet 379(9830):1984–1996PubMedCrossRef

Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF et al (2012) Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26(8):756–784PubMedCentralPubMedCrossRef

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812PubMedCentralPubMedCrossRef

Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 14(Suppl 5):v1–v49PubMedCentralPubMedCrossRef

Abrams DA, Hanson JA, Brown JM, Hsu FP, Delashaw JB Jr, Bota DA (2015) Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma. J Clin Neurosci. 22(1):35–39PubMedCrossRef

Jones TS, Holland EC (2012) Standard of care therapy for malignant glioma and its effect on tumor and stromal cells. Oncogene 31(16):1995–2006PubMedCrossRef

Drappatz J, Norden AD, Wen PY (2009) Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother 9(4):519–534PubMedCrossRef

Cher L, Rosenthal MA, Drummond KJ, Dally M, Murphy M, Ashley D et al (2008) The use of chemotherapy in patients with gliomas: patterns of care in Victoria from 1998–2000. J Clin Neurosci. 15(4):398–401PubMedCrossRef

10.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996PubMedCrossRef

11.

Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD et al (2000) A phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5):588–593PubMedCentralPubMedCrossRef

12.

Milano MT, Okunieff P, Donatello RS, Mohile NA, Sul J, Walter KA et al (2010) Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys 78(4):1147–1155PubMedCrossRef

13.

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5 year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5):459–466PubMedCrossRef

14.

Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15(19):6002–6007PubMedCrossRef

15.

Scherer HJ (1940) A critical review: the pathology of cerebral gliomas. J Neurol Psychiatry. 3(2):147–177PubMedCentralPubMedCrossRef

16.

McDonald KL, Aw G, Kleihues P (2012) Role of biomarkers in the clinical management of glioblastomas: what are the barriers and how can we overcome them? Front Neurol. 3:188PubMedCentralPubMed

17.

Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19(4):764–772PubMedCrossRef

18.

van den Bent MJ (2010) Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective. Acta Neuropathol 120(3):297–304PubMedCentralPubMedCrossRef

19.

Thuy MN, Kam JK, Lee GC, Tao PL, Ling DQ, Cheng M et al (2015) A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: analysis of 14,678 patients using systematic review and meta-analytical tools. J Clin Neurosci 22(5):785–799PubMedCrossRef

20.

Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A et al (2010) A multigene predictor of outcome in glioblastoma. Neuro Oncol. 12(1):49–57PubMedCentralPubMedCrossRef

21.

McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM et al (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455(7216):1061–1068CrossRef

22.

Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B et al (2009) Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 41(8):899–904PubMedCentralPubMedCrossRef

23.

Gan HK, Kaye AH, Luwor RB (2009) The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 16(6):748–754PubMedCrossRef

24.

Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3):157–173PubMedCrossRef

25.

Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110PubMedCentralPubMedCrossRef

26.

Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR et al (2013) The somatic genomic landscape of glioblastoma. Cell 155(2):462–477PubMedCentralPubMedCrossRef

27.

Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17(5):510–522PubMedCentralPubMedCrossRef

28.

Henriksen M, Johnsen KB, Olesen P, Pilgaard L, Duroux M (2014) MicroRNA expression signatures and their correlation with clinicopathological features in glioblastoma multiforme. Neuromol Med. 16(3):565–577CrossRef

29.

Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stuhler K, Meyer HE et al (2010) Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 20(3):539–550PubMedCrossRef

30.

Parker NR, Correia N, Crossley B, Buckland ME, Howell VM, Wheeler HR (2013) Correlation of MicroRNA 132 up-regulation with an unfavorable clinical outcome in patients with primary glioblastoma multiforme treated with radiotherapy plus concomitant and adjuvant temozolomide chemotherapy. Transl Oncol. 6(6):742–748PubMedCentralPubMedCrossRef

31.

Brower JV, Clark PA, Lyon W, Kuo JS (2014) MicroRNAs in cancer: glioblastoma and glioblastoma cancer stem cells. Neurochem Int 77:68–77PubMedPubMedCentralCrossRef

32.

Low SY, Ho YK, Too HP, Yap CT, Ng WH (2014) MicroRNA as potential modulators in chemoresistant high-grade gliomas. J Clin Neurosci. 21(3):395–400PubMedCrossRef

33.

Mizoguchi M, Guan Y, Yoshimoto K, Hata N, Amano T, Nakamizo A et al (2013) Clinical implications of microRNAs in human glioblastoma. Front Oncol. 3:19PubMedCentralPubMedCrossRef

34.

Hermansen SK, Kristensen BW (2013) MicroRNA biomarkers in glioblastoma. J Neurooncol 114(1):13–23PubMedCrossRef

35.

Moller HG, Rasmussen AP, Andersen HH, Johnsen KB, Henriksen M, Duroux M (2013) A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol 47(1):131–144PubMedCentralPubMedCrossRef

36.

Piwecka M, Rolle K, Belter A, Barciszewska AM, Zywicki M, Michalak M et al (2015) Comprehensive analysis of microRNA expression profile in malignant glioma tissues. Mol Oncol 9(7):1324–1340PubMedCrossRef

37.

Qu S, Guan J, Liu Y (2015) Identification of microRNAs as novel biomarkers for glioma detection: a meta-analysis based on 11 articles. J Neurol Sci 348(1–2):181–187PubMedCrossRef

38.

Wang Y, Gao X, Wei F, Zhang X, Yu J, Zhao H et al (2014) Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis. Gene 533(1):389–397PubMedCrossRef

39.

Guessous F, Alvarado-Velez M, Marcinkiewicz L, Zhang Y, Kim J, Heister S et al (2013) Oncogenic effects of miR-10b in glioblastoma stem cells. J Neurooncol 112(2):153–163PubMedCentralPubMedCrossRef

40.

Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M et al (2008) microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68(10):3566–3572PubMedCrossRef

41.

Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E et al (2009) MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 69(19):7569–7576PubMedCentralPubMedCrossRef

42.

Godlewski J, Nowicki MO, Bronisz A, Williams S, Otsuki A, Nuovo G et al (2008) Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 68(22):9125–9130PubMedCrossRef

43.

Gu JJ, Gao GZ, Zhang SM (2015) miR-218 inhibits the migration and invasion of glioma U87 cells through the Slit2-Robo1 pathway. Oncol Lett. 9(4):1561–1566PubMedCentralPubMed

44.

Wang RJ, Li JW, Bao BH, Wu HC, Du ZH, Su JL et al (2015) MicroRNA-873 (miRNA-873) inhibits glioblastoma tumorigenesis and metastasis by suppressing the expression of IGF2BP1. J Biol Chem 290(14):8938–8948PubMedCrossRef

45.

Rao SA, Santosh V, Somasundaram K (2010) Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol 23(10):1404–1417PubMedCrossRef

46.

Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO et al (2010) MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res 16(16):4289–4297PubMedCrossRef

47.

Visani M, de Biase D, Marucci G, Cerasoli S, Nigrisoli E, Bacchi Reggiani ML et al (2014) Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III. Mol Oncol. 8(2):417–430PubMedCrossRef

48.

Zhi F, Chen X, Wang S, Xia X, Shi Y, Guan W et al (2010) The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer 46(9):1640–1649PubMedCrossRef

49.

Rivera-Diaz M, Miranda-Roman MA, Soto D, Quintero-Aguilo M, Ortiz-Zuazaga H, Marcos-Martinez MJ et al (2015) MicroRNA-27a distinguishes glioblastoma multiforme from diffuse and anaplastic astrocytomas and has prognostic value. Am J Cancer Res. 5(1):201–218PubMedCentralPubMed

50.

Berthois Y, Delfino C, Metellus P, Fina F, Nanni-Metellus I, Al Aswy H et al (2014) Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O(6)-methylguanine methyltransferase and promotes temozolomide responsiveness. Cancer Biol Ther 15(7):938–950PubMedCentralPubMedCrossRef

51.

Barbano R, Palumbo O, Pasculli B, Galasso M, Volinia S, D’Angelo V et al (2014) A miRNA signature for defining aggressive phenotype and prognosis in gliomas. PLoS ONE 9(10):e108950PubMedCentralPubMedCrossRef

52.

Lages E, Guttin A, El Atifi M, Ramus C, Ipas H, Dupre I et al (2011) MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. PLoS ONE 6(5):e20600PubMedCentralPubMedCrossRef

53.

Conti A, Aguennouz M, La Torre D, Tomasello C, Cardali S, Angileri FF et al (2009) miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neurooncol 93(3):325–332PubMedCrossRef

54.

Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116(6):597–602PubMedCrossRef

55.

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773PubMedCentralPubMedCrossRef

56.

Lang MF, Yang S, Zhao C, Sun G, Murai K, Wu X et al (2012) Genome-wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. PLoS ONE 7(4):e36248PubMedCentralPubMedCrossRef

57.

Gal H, Pandi G, Kanner AA, Ram Z, Lithwick-Yanai G, Amariglio N et al (2008) MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. Biochem Biophys Res Commun. 376(1):86–90PubMedCrossRef

58.

Lavon I, Zrihan D, Granit A, Einstein O, Fainstein N, Cohen MA et al (2010) Gliomas display a microRNA expression profile reminiscent of neural precursor cells. Neuro Oncol. 12(5):422–433PubMedCentralPubMed

59.

Srinivasan S, Patric IR, Somasundaram K (2011) A ten-microRNA expression signature predicts survival in glioblastoma. PLoS ONE 6(3):e17438PubMedCentralPubMedCrossRef

60.

Zhang W, Zhang J, Yan W, You G, Bao Z, Li S et al (2013) Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer 119(4):814–824PubMedCrossRef

61.

Yan W, Li R, Liu Y, Yang P, Wang Z, Zhang C et al (2014) MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis. Oncotarget. 5(24):12908–12915PubMedCentralPubMedCrossRef

62.

Lakomy R, Sana J, Hankeova S, Fadrus P, Kren L, Lzicarova E et al (2011) MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci 102(12):2186–2190PubMedCrossRef

63.

Ma R, Yan W, Zhang G, Lv H, Liu Z, Fang F et al (2012) Upregulation of miR-196b confers a poor prognosis in glioblastoma patients via inducing a proliferative phenotype. PLoS ONE 7(6):e38096PubMedCentralPubMedCrossRef

64.

Qiu S, Lin S, Hu D, Feng Y, Tan Y, Peng Y (2013) Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med. 11:10PubMedCentralPubMedCrossRef

65.

Lu S, Wang S, Geng S, Ma S, Liang Z, Jiao B (2012) Increased expression of microRNA-17 predicts poor prognosis in human glioma. J Biomed Biotechnol. 2012:970761PubMedCentralPubMed

66.

Lai NS, Dong QS, Ding H, Miao ZL, Lin YC (2014) MicroRNA-210 overexpression predicts poorer prognosis in glioma patients. J Clin Neurosci. 21(5):755–760PubMedCrossRef

67.

Lu S, Wang S, Geng S, Ma S, Liang Z, Jiao B (2013) Upregulation of microRNA-224 confers a poor prognosis in glioma patients. Clin Transl Oncol 15(7):569–574PubMedCrossRef

68.

Sun J, Shi H, Lai N, Liao K, Zhang S, Lu X (2014) Overexpression of microRNA-155 predicts poor prognosis in glioma patients. Med Oncol 31(4):911PubMedCrossRef

69.

Men D, Liang Y, Chen L (2014) Decreased expression of microRNA-200b is an independent unfavorable prognostic factor for glioma patients. Cancer Epidemiol. 38(2):152–156PubMedCrossRef

70.

Hou SX, Ding BJ, Li HZ, Wang L, Xia F, Du F et al (2013) Identification of microRNA-205 as a potential prognostic indicator for human glioma. J Clin Neurosci. 20(7):933–937PubMedCrossRef

71.

Wang S, Lu S, Geng S, Ma S, Liang Z, Jiao B (2013) Expression and clinical significance of microRNA-326 in human glioma miR-326 expression in glioma. Med Oncol 30(1):373PubMedCrossRef

72.

Huang D, Qiu S, Ge R, He L, Li M, Li Y et al (2015) miR-340 suppresses glioblastoma multiforme. Oncotarget 6:9257–9270PubMedCentralPubMedCrossRef

73.

Guan Y, Chen L, Bao Y, Pang C, Cui R, Li G et al (2015) Downregulation of microRNA-504 is associated with poor prognosis in high-grade glioma. Int J Clin Exp Pathol. 8(1):727–734PubMedCentralPubMed

74.

Chang C, Shi H, Wang C, Wang J, Geng N, Jiang X et al (2012) Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma. Neurosci Lett 531(2):204–208PubMedCrossRef

75.

Bracken CP, Li X, Wright JA, Lawrence DM, Pillman KA, Salmanidis M et al (2014) Genome-wide identification of miR-200 targets reveals a regulatory network controlling cell invasion. EMBO J 33(18):2040–2056PubMedCentralPubMedCrossRef

76.

Stylli SS, Kaye AH, Lock P (2008) Invadopodia: at the cutting edge of tumour invasion. J Clin Neurosci. 15(7):725–737PubMedCrossRef

77.

Stylli SS, Stacey TT, Kaye AH, Lock P (2012) Prognostic significance of Tks5 expression in gliomas. J Clin Neurosci. 19(3):436–442PubMedCrossRef

78.

Parker NR, Khong P, Parkinson JF, Howell VM, Wheeler HR (2015) Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol. 5:55PubMedCentralPubMed

79.

Kim TM, Huang W, Park R, Park PJ, Johnson MD (2011) A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res 71(9):3387–3399PubMedCentralPubMedCrossRef

80.

Li R, Gao K, Luo H, Wang X, Shi Y, Dong Q et al (2014) Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma. J Exp Clin Cancer Res. 33:9PubMedCentralPubMedCrossRef

81.

Hayes J, Thygesen H, Tumilson C, Droop A, Boissinot M, Hughes TA et al (2015) Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature. Mol Oncol. 9(3):704–714PubMedCrossRef

82.

Haemmig S, Baumgartner U, Gluck A, Zbinden S, Tschan MP, Kappeler A et al (2014) miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas. Cell Death Dis 5:e1279PubMedPubMedCentralCrossRef

83.

Slaby O, Lakomy R, Fadrus P, Hrstka R, Kren L, Lzicarova E et al (2010) MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma. 57(3):264–269PubMedCrossRef

84.

Baraniskin A, Kuhnhenn J, Schlegel U, Maghnouj A, Zollner H, Schmiegel W et al (2012) Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro Oncol. 14(1):29–33PubMedCentralPubMedCrossRef

85.

Teplyuk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M et al (2012) MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol. 14(6):689–700PubMedCentralPubMedCrossRef

86.

Akers JC, Ramakrishnan V, Kim R, Phillips S, Kaimal V, Mao Y et al (2015) miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients. J Neurooncol 123(2):205–216PubMedCentralPubMedCrossRef

87.

Akers JC, Ramakrishnan V, Kim R, Skog J, Nakano I, Pingle S et al (2013) MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS ONE 8(10):e78115PubMedCentralPubMedCrossRef

88.

Liu Y, Zhang J, Han R, Liu H, Sun D, Liu X (2015) Downregulation of serum brain specific microRNA is associated with inflammation and infarct volume in acute ischemic stroke. J Clin Neurosci. 22(2):291–295PubMedCrossRef

89.

Sun XY, Lu J, Zhang L, Song HT, Zhao L, Fan HM et al (2015) Aberrant microRNA expression in peripheral plasma and mononuclear cells as specific blood-based biomarkers in schizophrenia patients. J Clin Neurosci. 22(3):570–574PubMedCrossRef

90.

Dong L, Li Y, Han C, Wang X, She L, Zhang H (2014) miRNA microarray reveals specific expression in the peripheral blood of glioblastoma patients. Int J Oncol 45(2):746–756PubMed

91.

Roth P, Wischhusen J, Happold C, Chandran PA, Hofer S, Eisele G et al (2011) A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem 118(3):449–457PubMedCrossRef

92.

Wang Q, Li P, Li A, Jiang W, Wang H, Wang J et al (2012) Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res. 31:97PubMedCentralPubMedCrossRef

93.

Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F et al (2013) Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer 132(1):116–127PubMedCrossRef

94.

Zhi F, Shao N, Wang R, Deng D, Xue L, Wang Q et al (2014) Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma. Neuro Oncol. doi:10.1371/journal.pone.0105734 PubMed

95.

Shao N, Wang L, Xue L, Wang R, Lan Q (2015) Plasma miR-454-3p as a potential prognostic indicator in human glioma. Neurol Sci. 36(2):309–313PubMedCrossRef

96.

Ilhan-Mutlu A, Wagner L, Wohrer A, Furtner J, Widhalm G, Marosi C et al (2012) Plasma MicroRNA-21 concentration may be a useful biomarker in glioblastoma patients. Cancer Invest 30(8):615–621PubMedCrossRef

97.

Lai NS, Wu DG, Fang XG, Lin YC, Chen SS, Li ZB et al (2015) Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer 112(Suppl):1241–1246PubMedCrossRef

98.

Zhang R, Pang B, Xin T, Guo H, Xing Y, Xu S et al (2015) Plasma miR-221/222 family as novel descriptive and prognostic biomarkers for glioma. Mol Neurobiol 48(1):37

99.

Wu J, Li L, Jiang C (2014) Identification and evaluation of serum MicroRNA-29 family for glioma screening. Mol Neurobiol. 1:1–7

100.

Wei X, Chen D, Lv T, Li G, Qu S (2014) Serum MicroRNA-125b as a Potential Biomarker for Glioma Diagnosis. Mol Neurobiol. 50:896–913CrossRef

101.

Manterola L, Guruceaga E, Gallego Perez-Larraya J, Gonzalez-Huarriz M, Jauregui P, Tejada S et al (2014) A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol. 16(4):520–527PubMedCentralPubMedCrossRef

102.

Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M et al (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10(12):1470–1476PubMedCentralPubMedCrossRef

103.

Siegal T (2015) Clinical impact of molecular biomarkers in gliomas. J Clin Neurosci. 22(3):437–444PubMedCrossRef

104.

Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G et al (2005) Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 334(4):1351–1358PubMedCrossRef

105.

Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65(14):6029–6033PubMedCrossRef

106.

Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M et al (2008) miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 6:14PubMedCentralPubMedCrossRef

107.

Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E (2009) MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer 125(6):1407–1413PubMedCrossRef

108.

Hua D, Mo F, Ding D, Li L, Han X, Zhao N et al (2012) A catalogue of glioblastoma and brain MicroRNAs identified by deep sequencing. OMICS 16(12):690–699PubMedCentralPubMedCrossRef

109.

Skalsky RL, Cullen BR (2011) Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS ONE 6(9):e24248PubMedCentralPubMedCrossRef

110.

Sana J, Radova L, Lakomy R, Kren L, Fadrus P, Smrcka M et al (2014) Risk score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients. Carcinogenesis 35(12):2756–2762PubMedCrossRef

111.

Zadran S, Remacle F, Levine R (2014) Surprisal analysis of glioblastoma multiform (GBM) microRNA dynamics unveils tumor specific phenotype. PLoS ONE 9(9):e108171PubMedCentralPubMedCrossRef

Titel: MicroRNA as potential biomarkers in Glioblastoma
verfasst von: Zammam Areeb
Stanley S. Stylli
Rachel Koldej
David S. Ritchie
Tali Siegal
Andrew P. Morokoff
Andrew H. Kaye
Rodney B. Luwor
Publikationsdatum: 01.11.2015
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2015
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-015-1912-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients

Location of brain tumor intersecting white matter tracts predicts patient prognosis

Co-expression of COX-2 and 5-LO in primary glioblastoma is associated with poor prognosis

Susceptibility-weighted imaging and diffusion-weighted imaging findings in central nervous system monomorphic B cell post-transplant lymphoproliferative disorder before and after treatment and comparison with primary B cell central nervous system lymphoma

Nomogram prediction of survival in patients with brain metastases from hepatocellular carcinoma treated with whole-brain radiotherapy: a multicenter retrospective study